secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628908-25-000112
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q2 revenue falls 31% to $444M, net loss deepens to $51M; raises FY profitability outlook
--------------------------------------------------------------------------------

- Revenue $444.3M, down 31% YoY from $647.1M; net loss $51.1M vs $6.4M loss in prior year.
- Adjusted EBITDA $37.5M (8.5% margin) vs $51.9M (8.0% margin); margin improved but absolute EBITDA down 28%.
- Performance Suite average lives 6,490, down 6% YoY; average PMPM fee $13.76, down 38% YoY.
- CEO says company exceeded EBITDA targets and raised full-year profitability outlook; expects to exceed historical growth rates in 2026.
- Year-to-date new revenue agreements total 11; multiple new client additions across Performance Suite and specialty services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000112/0001628908-25-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000112/evh-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628908-25-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer